Clinical and biomarker predictors of side effects from tamoxifen
about
Body weight management in overweight and obese breast cancer survivorsThe active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cellsPhenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium.Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopauseTamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice.Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI SwitchTamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.Breast reconstruction after mastectomy: does it decrease depression at the long-term?Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast CancerCan polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients.Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.Hot flashes in breast cancer survivors: Frequency, severity and impact.The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
P2860
Q24186086-F784A95A-04BC-4F9A-AD42-5D7C6765D3E0Q28546094-F0458F41-ACC8-4991-BF75-293132E75E31Q30727473-82CD8384-C8D3-4D8E-86EE-8351AD7AA081Q34532021-624D8248-30F8-445A-8BE5-A856B8C378A4Q35020403-703F3775-52C6-464A-88CB-59832038CE0CQ35076890-3F41977D-8CF2-4609-BEDD-D9528474B491Q35666599-98FCCDD0-E7AE-4196-9956-A89839D3CDB9Q35747766-4A093303-2D70-4282-BF35-4B328735A11FQ35768721-8EFB693F-DC4A-4D18-AC7E-88492374172BQ36502027-69845170-C37D-4DBE-81C9-7CAC88374319Q36586900-A76D6300-903C-4CB8-8325-9A0D62216693Q37091133-E39F09A6-858B-4DFB-928A-CC3169A17498Q37147559-258B4511-3520-46F4-853C-9D54A04BC24FQ38141971-99D809E5-AD57-4A07-B380-93C5EDCE0CC2Q38876325-51F07E7C-894A-4F2F-978D-740B1BC30E6FQ39042324-AAF5BA72-1BEC-4362-B27C-6CD87729140DQ39052545-6E1F16A1-D644-4D17-B647-A3AAB6271E92Q39162361-F24E2BE8-3E98-4299-B870-A692BBAF06C9Q40197891-C4A8FC11-0473-4B9C-9B32-E55AFCE64B01Q41558055-8CDC25FA-CE65-4D79-B463-600F3365AD64Q44899685-10B3EB32-A2BD-41C8-83F0-4DB183EA7320Q47776503-99FD99B6-2349-406D-B279-E80303081C24Q48068021-8160C2DB-AF3D-4A3F-907D-EE4EAAEDF0B5Q55519528-AFC21636-CE85-4ED4-8811-1F13F85B79A3
P2860
Clinical and biomarker predictors of side effects from tamoxifen
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Clinical and biomarker predictors of side effects from tamoxifen
@ast
Clinical and biomarker predictors of side effects from tamoxifen
@en
type
label
Clinical and biomarker predictors of side effects from tamoxifen
@ast
Clinical and biomarker predictors of side effects from tamoxifen
@en
prefLabel
Clinical and biomarker predictors of side effects from tamoxifen
@ast
Clinical and biomarker predictors of side effects from tamoxifen
@en
P2093
P2860
P1476
Clinical and biomarker predictors of side effects from tamoxifen
@en
P2093
Alan H B Wu
Karla Kerlikowske
Mary S Beattie
Simone Tchu
Wendy Lorizio
P2860
P2888
P304
P356
10.1007/S10549-011-1893-4
P407
P577
2011-12-30T00:00:00Z